LEPU BIO Shares Surge Again, Gaining Over 7% on Promising Drug Candidate

Stock News07-15 10:30

Shares of LEPU BIO (02157) have surged more than 7%, extending a monthly gain of nearly 30%. At the time of writing, the stock is up 6.01% to HK$4.94, with a turnover of HK$32.62 million.

The catalyst for the move is the formal acceptance of the clinical trial application for MRG007 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in May. This marks a crucial step in the company's clinical development for gastrointestinal cancer, potentially offering a new treatment option for millions of patients with advanced disease in China.

Analysts note that MRG007, a key pipeline asset for which LEPU BIO secured a landmark $1.2 billion overseas licensing deal, represents a significant milestone in its global development. With its differentiated technological advantages, MRG007 has the potential to become a best-in-class (BIC) drug candidate. This progress is expected to solidify the company's leading position in the ADC (antibody-drug conjugate) field for gastrointestinal cancer and lay a solid foundation for future global multi-center clinical trials and potential further business development collaborations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193879863?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193879863","market":"fut","top_or_hot":-1,"title":"LEPU BIO Shares Surge Again, Gaining Over 7% on Promising Drug Candidate","media":"Stock News","content":"<p>Shares of <b>LEPU BIO</b> (<b>02157</b>) have surged more than 7%, extending a monthly gain of nearly 30%. At the time of writing, the stock is up 6.01% to HK$4.94, with a turnover of HK$32.62 million.<br><br>\nThe catalyst for the move is the formal acceptance of the clinical trial application for MRG007 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in May. This marks a crucial step in the company's clinical development for gastrointestinal cancer, potentially offering a new treatment option for millions of patients with advanced disease in China.<br><br>\nAnalysts note that MRG007, a key pipeline asset for which LEPU BIO secured a landmark $1.2 billion overseas licensing deal, represents a significant milestone in its global development. With its differentiated technological advantages, MRG007 has the potential to become a best-in-class (BIC) drug candidate. This progress is expected to solidify the company's leading position in the ADC (antibody-drug conjugate) field for gastrointestinal cancer and lay a solid foundation for future global multi-center clinical trials and potential further business development collaborations.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEPU BIO Shares Surge Again, Gaining Over 7% on Promising Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEPU BIO Shares Surge Again, Gaining Over 7% on Promising Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-15 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>LEPU BIO</b> (<b>02157</b>) have surged more than 7%, extending a monthly gain of nearly 30%. At the time of writing, the stock is up 6.01% to HK$4.94, with a turnover of HK$32.62 million.<br><br>\nThe catalyst for the move is the formal acceptance of the clinical trial application for MRG007 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in May. This marks a crucial step in the company's clinical development for gastrointestinal cancer, potentially offering a new treatment option for millions of patients with advanced disease in China.<br><br>\nAnalysts note that MRG007, a key pipeline asset for which LEPU BIO secured a landmark $1.2 billion overseas licensing deal, represents a significant milestone in its global development. With its differentiated technological advantages, MRG007 has the potential to become a best-in-class (BIC) drug candidate. This progress is expected to solidify the company's leading position in the ADC (antibody-drug conjugate) field for gastrointestinal cancer and lay a solid foundation for future global multi-center clinical trials and potential further business development collaborations.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1193879863","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193879863","pubTimestamp":1784082623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of LEPU BIO (02157) have surged more than 7%, extending a monthly gain of nearly 30%. At the time of writing, the stock is up 6.01% to HK$4.94, with a turnover of HK$32.62 million. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF","02157":"乐普生物"},"translate_title":"乐普生物股价再次飙升，候选药物前景光明，涨幅超7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1,"02157":1,"VXUS":1},"content_text":"Shares of LEPU BIO (02157) have surged more than 7%, extending a monthly gain of nearly 30%. At the time of writing, the stock is up 6.01% to HK$4.94, with a turnover of HK$32.62 million.\nThe catalyst for the move is the formal acceptance of the clinical trial application for MRG007 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in May. This marks a crucial step in the company's clinical development for gastrointestinal cancer, potentially offering a new treatment option for millions of patients with advanced disease in China.\nAnalysts note that MRG007, a key pipeline asset for which LEPU BIO secured a landmark $1.2 billion overseas licensing deal, represents a significant milestone in its global development. With its differentiated technological advantages, MRG007 has the potential to become a best-in-class (BIC) drug candidate. This progress is expected to solidify the company's leading position in the ADC (antibody-drug conjugate) field for gastrointestinal cancer and lay a solid foundation for future global multi-center clinical trials and potential further business development collaborations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193879863","isCrawlerRequest":true}